- Home
- BESS vs ITRM Comparison
BESS vs ITRM Comparison
Compare BESS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BESS | ITRM |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Ireland |
| Employees | 3 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BESS | ITRM |
|---|---|---|
| Price | $2.30 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 29.6K | ★ 30.9M |
| Earning Date | 03-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $0.03 |
| 52 Week High | $3.60 | $1.16 |
Technical Indicators
Market Signals| Indicator | BESS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 26.10 |
| Support Level | $2.06 | N/A |
| Resistance Level | $3.04 | $0.39 |
| Average True Range (ATR) | 0.24 | 0.02 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 2.70 | 3.34 |
Price Performance
Historical ComparisonAbout BESS Bimergen Energy Corporation Common Stock
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.